Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Indoprofen”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 109 records · Page 6Linked to original sources
PubMed1985

Indoprofen--a new non-opioid analgesic. A comparison with pethidine.

Indoprofen (400 mg), a non-opioid, non-steroidal anti-inflammatory drug, was compared on a random, double-blind basis with pethidine (1,5 mg/kg) after elective caesarean section (40 patients) and after orthopaedic surgery (40 patients). The drugs were given intravenously during anaesthesia and provided adequate analgesia for a period of up to 2 hours postoperatively. No significant differences between the two drugs were noted in terms of efficacy and side-effects.

Adolescent↗
PubMed1983

[New contributions on extinction tests of essential headache. II. The test with indoprofen].

The authors described the results about the action of indoprofen (i.v. 400 mg) in three subjects affected by premenstrual migraine. They showed decreased levels of PGF2 alpha in the cerebrospinal fluid evaluated by gas-chromatography and mass spectrometry. The samples were extracted at 0, 15, 30 and 45 minutes. The levels of pain, was also decreased, they were evaluated by the analogic visual scale (V.A.S.).

Adult↗
PubMed1982

Renal effects of indoprofen in rhesus monkeys.

The non-steroidal anti-inflammatory analgesic alpha-[4-(1-oxo-2-iso-indolinyl)-phenyl]propionic acid (indoprofen) was given p.o. in gelatin capsules to six groups of six Rhesus monkeys (three males and three females/group) for 15 months. Group I (five males and five females) served as control and was given empty gelatin capsules. The following daily doses were used: Group 2--20 mg/kg b.i.d.; Group 3--40 mg/kg q.d.; Group 4--30 mg/kg b.i.d.; Group 5--60 mg/kg q.d.; Group 6--40 mg/kg b.i.d. and Group 7--80 mg/kg q.d. Except for some elevated blood urea nitrogen levels after 12 months in the animals of Group 7, no changes in clinical function test values, absolute and relative kidney weights or renal gross abnormalities were found. The renal papillae and pelves were normal and not affected in all monkeys. The microscopic examination revealed a focal chronic interestitial nephritis in some of the monkeys. In the survivors the incidence of this disease increased from one out of ten control animals to three out of five monkeys in Group 7 (80 mg/kg/d). However, this quantal, statistically significant difference became biologically irrelevant and no longer statistically significant when these microscopic changes were quantified. The most severe case was seen in the control animal and the least pronounced in monkeys having received 80 mg/kg/d. When these cases of interstitial nephritis were further evaluated using a multifactorial point sampling procedure, no significant quantitative changes in renal tissue components, indicative of analgesic-induced nephropathy, were detectable.

Animals↗
PubMed1980

Tissue distribution of 14C-indoprofen in the rat.

The tissue distribution of 14C-labelled 2-[p-(1-oxo-2-isoindolinyl)phenyl)propionic acid (indoprofen) after i.v. injection was studied in male and pregnant rats by whole-body autoradiography. Distribution was characterized by a rapid localization in the liver, kidneys and lungs. A significant amount of radioactivity found in the intestinal contents suggested biliary excretion. There was no indication of retention of the drug in the brain. In pregnant rats, radioactivity crossed the blood-placenta barrier to a moderate extent and low concentrations were found in foetuses.

Animals↗
PubMed1981

Evaluation of the long-term efficacy and safety of indoprofen in rheumatoid arthritis and osteoarthritis patients.

Thirty-seven adult out-patients of both sexes, suffering from classical or definite rheumatoid arthritis (R.A.) or osteoarthritis (O.A.), were given indoprofen 600 mg/day for up to 5 months, in order to evaluate its effectiveness and safety. A significant improvement of joint tenderness (Ritchie) and of functional index (Lee) was rapidly achieved in R.A. patients (12 cases); objective signs of inflammation, moreover, were gradually relieved. In O.A. patients (25 cases) articular pain, motility and swelling all improved in about 90% of cases. A complete set of laboratory tests reflecting blood picture, liver and kidney function, carried out at monthly intervals during the study, failed to reveal any sign of toxicity. Clinical tolerance was generally good.

Aged↗
PubMed1975

Double-blind study of the analgesic effect of indoprofen (K 4277).

In a double-blind study, indoprofen was superior to placebo in decreasing pain in patients with primary and metastatic cancer and with neuralgia. A single oral dose of 200 mg was more active than a 100-mg dose. The preferences of patients proved to be a more sensitive parameter in this study than scores of pain intensity, pain relief, and other related measurements (SPID, TOTPAR, and Peak PID).

Adult↗
PubMed1977

Indoprofen in knee joint osteoarthritis: a double-blind, crossover clinical trial.

A double-blind, crossover clinical trial has been carried out in subjects with knee joint osteoarthritis to assess the activity of two nonsteroidal antiinflammatory drugs. Eighteen outpatients with a severe systemic form were given orally indoprofen (800 mg/day), indomethacin (80 mg/day), and placebo for one week without interval between treatment periods. Significant improvement was seen in subjective and objective signs and symptoms after both drugs, which gave similar results. No significant differences between drugs were noted as to patients' opinions and preferences, which were in agreement with clinical indexes. No improvement in most cases and deterioration in a few subjects followed placebo administration, probably because the majority of the sample was made up of placebo non-reactors. Consequently, the activity data of the trial might be interpreted as expression of the pure pharmacologic activity of the tested drugs. Safety was very satisfactory: patients complained only rarely of trivial and clinically unimportant side effects; no variations in laboratory tests were noted.

Adult↗
PubMed1984

[Action of indoprofen on atrio-ventricular conduction. Preliminary note].

The purpose of the present study was to evaluate the possible electrophysiological effects of Indoprophene, a new non steroidal analgesic anti-inflammatory agent, which might be employed in the treatment of chest-pain from myocardial ischemia. Ten patient, who were undergoing a electrophysiological study for diagnostic purposes, were given 400 mg of indoprophene by intravenous rapid bolus. The A-V conduction times were recorded in basic condition and 30 minutes after administration of the drug. The data we collected show that Indoprophene does not influences either normal or prolonged A-V conduction times. We conclude that the drug, as it has a good effect on pain and lacks haemodynamic consequences and effects on conduction and excitability, is recommendable for the treatment of chest-pain from myocardial ischemia.

Aged↗